论文部分内容阅读
目的观察低分子肝素联合葛根素治疗急性一氧化碳中毒迟发性脑病(DEACMP)的临床效果。方法选取医院收治的诊断为DEACMP患者30例,随机分为研究组和对照组,每组15例。对照组给予常规治疗,研究组在对照组基础上加用低分子肝素和葛根素。观察2组临床疗效、血液流变学变化及药物不良反应发生情况。结果研究组总有效率为86.7%,高于对照组的66.7%(P<0.05)。研究组治疗后纤维蛋白原水平、血浆黏度、全血低切黏度、全血高切黏度均较治疗前和对照组均降低,差异有统计学意义(P<0.05)。2组治疗期间均未发生严重不良反应。结论葛根素联合低分子肝素治疗DEACMP患者疗效确切,安全性高。
Objective To observe the clinical effect of low molecular weight heparin combined with puerarin on the treatment of acute carbon monoxide poisoning delayed encephalopathy (DEACMP). Methods Thirty patients diagnosed as DEACMP admitted to hospital were randomly divided into study group and control group, with 15 cases in each group. Control group was given routine treatment, the study group in the control group based on the use of low molecular weight heparin and puerarin. The clinical curative effect, hemorheological changes and adverse drug reactions in the two groups were observed. Results The total effective rate was 86.7% in the study group, which was higher than 66.7% in the control group (P <0.05). The levels of fibrinogen, plasma viscosity, whole blood low shear viscosity and whole blood high shear viscosity of the study group after treatment were lower than those before treatment and the control group, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in the two groups during the treatment. Conclusion Puerarin combined with low molecular weight heparin in the treatment of DEACMP patients with effective and safe.